As of today (2024-04-23), Dr Reddy's Laboratories's share price is $71.49.
Dr Reddy's Laboratories's Owner Earnings per Share (TTM) ended in Dec. 2023 was $4.25. It's Price-to-Owner-Earnings for today is 16.82.
The historical rank and industry rank for Dr Reddy's Laboratories's Price-to-Owner-Earnings or its related term are showing as below:
RDY'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.9 Med: 40.18 Max: 1935.63
Current: 16.83
During the past 13 years, the highest Price-to-Owner-Earnings of Dr Reddy's Laboratories was 1935.63. The lowest was 11.90. And the median was 40.18.
As of today (2024-04-23), Dr Reddy's Laboratories's share price is $71.49.
Dr Reddy's Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.79. Therefore, Dr Reddy's Laboratories's PE Ratio for today is 18.88.
As of today (2024-04-23), Dr Reddy's Laboratories's share price is $71.49.
Dr Reddy's Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in was $3.61. Therefore, Dr Reddy's Laboratories's PE Ratio without NRI for today is 19.80.
During the past 13 years, Dr Reddy's Laboratories's highest PE Ratio without NRI was 48.24. The lowest was 15.37. And the median was 25.65.
Dr Reddy's Laboratories Price-to-Owner-Earnings Historical Data
The historical data trend for Dr Reddy's Laboratories's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Dr Reddy's Laboratories Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Price-to-Owner-Earnings |
|
Get a 7-Day Free Trial
|
|
|
23.14 |
65.05 |
52.92 |
44.94 |
14.13 |
|
Dr Reddy's Laboratories Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Owner-Earnings |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
31.17 |
14.13 |
15.21 |
12.64 |
16.37 |
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories Price-to-Owner-Earnings Distribution
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's Price-to-Owner-Earnings falls into.
Dr Reddy's Laboratories Price-to-Owner-Earnings Calculation
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Dr Reddy's Laboratories's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description
Traded in Other Exchanges
Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Dr Reddy's Laboratories (Dr Reddy's Laboratories) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RDY has been successfully added to your